Hexadecyl- phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial
AbstractA placebo- controlled trial compared 6% hexadecyl- phosphorylcholine [HePC] and 12% benzethonium chloride ointment with placebo ointment for treatment of cutaneous leishmaniasis. Cutaneous lesions were experimentally induced by inoculation with leishmania promastigotes in 60 golden hamsters. Forty  animals were treated with drug and 20 with placebo ointment applied twice daily for 15 days. After treatment, all lesions were significantly reduced in size in the treatment group compared with the placebo ointment. No parasites were detected in smears from 35/ 40 of the drug- treated lesions and no relapses occurred over 120 days of observation
Iqbal, J., Bukhari, I., Jamshid, M., Bashir, S., Masoom Yasinzai M. et al. (2006). Hexadecyl- phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial. EMHJ - Eastern Mediterranean Health Journal, 12 (5), 685-689, 2006 https://apps.who.int/iris/handle/10665/117137
JournalEMHJ - Eastern Mediterranean Health Journal, 12 (5), 685-689, 2006
MetadataShow full item record
Showing items related by title and subject
Cutaneous leishmaniasis: control in selected countries of the WHO Eastern Mediterranean and African Regions: report of an interregional network meeting, Casablanca, Morocco, 23–24 June 2014 World Health Organization (World Health Organization, 2015)
Effectiveness of meglumine antimoniate against L.tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran Karamian, M.; Faroghi Bojd, M.S.; Salehabadi, A.; Hemmati, M.; Barati, D.A. (World Health Organization, Regional Office for the Eastern Mediterranean, 2015)With limited options to treat cutaneous leishmaniasis, constant monitoring of the rate of resistance to pentavalent antimony-based drugs is needed. This study identified the infecting Leishmania species and evaluated the ...